Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 275

The DOI matches its Crossref record.

Long-term Outcomes After Autologous Hematopoietic Stem Cell Transplantation for Multiple Sclerosis

Open access
Muraro, Paolo A., Pasquini, Marcelo, Atkins, Harold L., Bowen, James D., Farge, Dominique, Fassas, Athanasios, Freedman, Mark S., Georges, George E., Gualandi, Francesca, Hamerschlak, Nelson, Havrdova, Eva, Kimiskidis, Vassilios K., Kozak, Tomas, Mancardi, Giovanni L., Massacesi, Luca, Moraes, Daniela A., Nash, Richard A., Pavletic, Steven, Ouyang, Jian, Rovira, Montserrat, Saiz, Albert, Simoes, Belinda, Trnený, Marek, Zhu, Lin, Badoglio, Manuela, Zhong, Xiaobo, Sormani, Maria Pia, Saccardi, Riccardo, for the Multiple Sclerosis–Autologous Hematopoietic Stem Cell Transplantation (MS-AHSCT) Long-term Outcomes Study Group·2017·JAMA Neurology

Abstract

IMPORTANCE: Autologous hematopoietic stem cell transplantation (AHSCT) may be effective in aggressive forms of multiple sclerosis (MS) that fail to respond to standard therapies. OBJECTIVE: To evaluate the long-term outcomes in patients who underwent AHSCT for the treatment of MS in a large multicenter cohort. DESIGN, SETTING, AND PARTICIPANTS: Data were obtained in a multicenter, observational, retrospective cohort study. Eligibility criteria were receipt of AHSCT for the treatment of MS between January 1995 and December 2006 and the availability of a prespecified minimum data set comprising the disease subtype at baseline; the Expanded Disability Status Scale (EDSS) score at baseline; information on the administered conditioning regimen and graft manipulation; and at least 1 follow-up visit or report after transplant. The last patient visit was on July 1, 2012. To avoid bias, all eligible patients were included in the analysis regardless of their duration of follow-up. Data analysis was conducted from September 1, 2014 to April 27, 2015. EXPOSURES: Demographic, disease-related, and treatment-related exposures were considered variables of interest, including age, disease subtype, baseline EDSS score, number of previous disease-modifying treatments, and intensity of the conditioning regimen. MAIN OUTCOMES AND MEASURES: The primary outcomes were MS progression-free survival and overall survival. The probabilities of progression-free survival and overall survival were calculated using Kaplan-Meier survival curves and multivariable Cox proportional hazards regression analysis models. RESULTS: Valid data were obtained from 25 centers in 13 countries for 281 evaluable patients, with median follow-up of 6.6 years (range, 0.2-16 years). Seventy-eight percent (218 of 281) of patients had progressive forms of MS. The median EDSS score before mobilization of peripheral blood stem cells was 6.5 (range, 1.5-9). Eight deaths (2.8%; 95% CI, 1.0%-4.9%) were reported within 100 days of transplant and were considered transplant-related mortality. The 5-year probability of progression-free survival as assessed by the EDSS score was 46% (95% CI, 42%-54%), and overall survival was 93% (95% CI, 89%-96%) at 5 years. Factors associated with neurological progression after transplant were older age (hazard ratio [HR], 1.03; 95% CI, 1.00-1.05), progressive vs relapsing form of MS (HR, 2.33; 95% CI, 1.27-4.28), and more than 2 previous disease-modifying therapies (HR, 1.65; 95% CI, 1.10-2.47). Higher baseline EDSS score was associated with worse overall survival (HR, 2.03; 95% CI, 1.40-2.95). CONCLUSIONS AND RELEVANCE: In this observational study of patients with MS treated with AHSCT, almost half of them remained free from neurological progression for 5 years after transplant. Younger age, relapsing form of MS, fewer prior immunotherapies, and lower baseline EDSS score were factors associated with better outcomes. The results support the rationale for further randomized clinical trials of AHSCT for the treatment of MS.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1001/jamaneurol.2016.5867

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 275

Metadata

Authors
Muraro, P. A., Pasquini, M., Atkins, H. L., Bowen, J. D., Farge, D., Fassas, A., Freedman, M. S., Georges, G. E., Gualandi, F., Hamerschlak, N., Havrdova, E., Kimiskidis, V. K., Kozak, T., Mancardi, G. L., Massacesi, L., Moraes, D. A., Nash, R. A., Pavletic, S., Ouyang, J., Rovira, M., Saiz, A., Simoes, B., Trnený, M., Zhu, L., Badoglio, M., Zhong, X., Sormani, M. P., Saccardi, R., & for the Multiple Sclerosis–Autologous Hematopoietic Stem Cell Transplantation (MS-AHSCT) Long-term Outcomes Study Group
Venue
JAMA Neurology
Published
2017-04-01
Volume
74
Issue
4
Pages
459
ISSN
2168-6149 (ISSN-L)
OpenAlex
W2593002358
Cited by
275
References
0
FWCI
23.18
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Long-term Outcomes After Autologous Hematopoietic Stem Cell Transplantation for Multiple Sclerosis. https://app.cochat.ai/papers/10.1001/jamaneurol.2016.5867
The paper
Muraro, P. A., Pasquini, M., Atkins, H. L., Bowen, J. D., Farge, D., Fassas, A., Freedman, M. S., Georges, G. E., Gualandi, F., Hamerschlak, N., Havrdova, E., Kimiskidis, V. K., Kozak, T., Mancardi, G. L., Massacesi, L., Moraes, D. A., Nash, R. A., Pavletic, S., Ouyang, J., . . . for the Multiple Sclerosis–Autologous Hematopoietic Stem Cell Transplantation (MS-AHSCT) Long-term Outcomes Study Group. (2017). Long-term Outcomes After Autologous Hematopoietic Stem Cell Transplantation for Multiple Sclerosis. JAMA Neurology. https://doi.org/10.1001/jamaneurol.2016.5867

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.